Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2007
02/13/2007US7176236 Water-soluble etoposide analogs and methods of use thereof
02/13/2007US7176235 10,11-Dehydroepothilones; anticancer, antiproliferative and antiarthritic agents
02/13/2007US7176234 Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
02/13/2007US7176233 Salinosporamides and methods for use thereof
02/13/2007US7176232 Fermentation product of marine actinomyces strains; antiproliferative agents; anticancer agents
02/13/2007US7176231 For example, 5-acetyl-3-{[4-(diethylaminomethyl)-phenylamino]-phenyl-methylidene}-2-indolinone; for treatment of diabetes mellitus, diabetes associated disorders such as diabetic neuropathy, degenerative neurological diseases such as Alzheimer's disease, stroke, neurotraumatic injuries, bipolar disorders
02/13/2007US7176230 For example, N-benzenesulfonyl-3-(5'-hydroxymethyl-2'-furyl)indole; anticoagulants, vasodilators
02/13/2007US7176229 Pyrrolidine antiinflammatory agents for rheumatoid arthritis, osteoarthritis; antiallergens for asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome, chronic pulmonary inflammatory disease; reduce or eliminate adverse CNS side effects associated with prior PDE4 inhibitors
02/13/2007US7176228 Amidobiphenyloxime derivatives, useful as fungicide or bactericide for protection of crops and materials
02/13/2007US7176225 For example, (6aR,7aS,8S,11aS)-5,8-bis(dimethylamino)-2-(2,2-diphenylvinyl)-9,11a,12-trihydroxy-11,13-dioxo-6,6a,7,7a,8,11,11a,13-octahydrotetraceno[2,1-d][1,3]oxazole-10-carboxamide; useful against antibiotic resistant organisms
02/13/2007US7176224 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists
02/13/2007US7176223 5-(3-Pyridylmethyl)imidazolidine-2,4-dione is subjected to a hydrolysis reaction, wherein the reaction is followed by a decarbamation reaction to obtain (3-pyridyl)alanine
02/13/2007US7176222 Contacting a base with an enantiomerically pure hydroxyl group containing compound, reacting the product with a nitro, fluoro-containing benzene compound, reducing the product to the corresponding amine
02/13/2007US7176221 Low dose pharmaceutical composition having uniform drug distribution and potency
02/13/2007US7176220 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
02/13/2007US7176219 Salts of quinuclidine derivative
02/13/2007US7176218 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
02/13/2007US7176217 such as N-Hydroxy-2-[(4-methoxyphenyl)sulfonyl]-2-azabicyclo[2.2.1]heptane-3-carboxamide, used in cosmetics or drugs as gelatinase inhibitors, for preventing skin aging or wrinkling; preventing diseases due to abnormal metabolism of tissue matrices such as arthritis, ulcers, metastasis or tumors
02/13/2007US7176216 Antagonist for corticotropin-releasing factor receptors
02/13/2007US7176215 Bicyclic oxopyridine and oxopyrimidine derivatives
02/13/2007US7176214 Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
02/13/2007US7176213 For example, 1-(9-benzylamino-10-cyano-imidazo[1,2-a]quinolin-2-carbonyl)pyrrolidine; may be used for the treatment of diseases such as asthma, glaucoma, tumors, allergic and inflammatory diseases, ischemia, hypoxia, arrythmia and renal diseases
02/13/2007US7176212 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
02/13/2007US7176211 For example, 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione; use in treating prostate cancer, benign prostatic hypertrophy, breast cancer and endometriosis
02/13/2007US7176210 Cannabinoid receptor ligands and uses thereof
02/13/2007US7176208 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
02/13/2007US7176207 Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis
02/13/2007US7176206 Antibiotics
02/13/2007US7176205 Bi-pyridinyl derivatives as NK-1 antagonists
02/13/2007US7176204 Substituted carboxylic acid derivatives
02/13/2007US7176203 Imidazo-triazine derivatives as ligands for gaba receptors
02/13/2007US7176202 Such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders, rheumatoid arthritis
02/13/2007US7176201 Modulation of anxiety through blockade of anandamide hydrolysis
02/13/2007US7176200 Derivatives of sulphonamides, their preparation and use as medicaments
02/13/2007US7176199 Useful as a preventive or/and a therapeutic agent for a disease in which alpha v beta 3 integrin is involved
02/13/2007US7176198 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
02/13/2007US7176197 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
02/13/2007US7176196 Bicyclic heterocycles as HIV integrase inhibitors
02/13/2007US7176195 Treatment of nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence or bleeding disorders such a hemophilia
02/13/2007US7176194 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
02/13/2007US7176193 Antilipemic agents; therapy for insulin resistance
02/13/2007US7176192 Method for treating patients for radiation exposure
02/13/2007US7176191 Bi phosphate containing protonated compound with two end groups; disinfecting surfaces of surgical equipments and skin
02/13/2007US7176190 Comprises transgenic potato which generates starch with modified viscosity and phosphate characteristics; for enhancing quality of paper, cardboard, adhesive, textile, plaster, concrete, fertilizer, medicine and toothpaste; improving animal feeds
02/13/2007US7176189 Methods for regeneration of a mammalian lens
02/13/2007US7176188 Method of lethally sensitizing human and animal cells
02/13/2007US7176187 Fusion proteins based upon somatostatin receptors
02/13/2007US7176181 Enhancement or inhibition of the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors; the use of modulators of cell adhesion; antitumor, -carcinogenic, -metastasis agents
02/13/2007US7176180 Fusion proteins; immunoglobulins; kits
02/13/2007US7176178 Protein H and its fragments/derivatives are capable of interacting with nucleophosmin/B23, actin, NPM/B23, protein SET or hnRNP A2/B1
02/13/2007US7176164 1,3-selenazolin derivatives and process for preparing the same
02/13/2007US7176163 Pharmacological effect potentiators for pesticides
02/13/2007US7175994 Lactacystin, a peptidyl aldehyde, or a peptidyl epoxy ketone inhibits proteasomal activity; epidermal growth factor, a fibroblast growth factor, a platelet-derived growth factor, a transforming growth factor, a parathyroid hormone, etc for promoting skin tissue growth, an excipient
02/13/2007US7175987 administering to mammals mixtures of plant extracts from ginger, green tea, turmeric, horseradish and carriers
02/13/2007US7175859 aqueous extract of stems or leaves or stems and leaves of one or more Cissus quandragularis plants to promote weight loss; combined with chitosan and amylase inhibitor
02/13/2007US7175858 flowable composition that sets into a solid calcium phosphate containing product; for the repair of hard tissue defects, e.g., bone defects
02/13/2007US7175856 Mixing drug with arginine; reduction of bitter taste
02/13/2007US7175855 Ziprasidone suspension
02/13/2007US7175854 Pharmaceutical preparation comprising an active dispersed on a matrix
02/13/2007US7175853 Therapeutic system which can be moisture-activated
02/13/2007US7175850 Formulation for topical non-invasive application in vivo
02/13/2007US7175844 Administering an agent that inhibits a component of the VEGF signal transduction pathway; agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
02/13/2007US7175840 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
02/13/2007US7175837 Stimulation of said skin's stratum corneum turnover rate; also contains surfactant(s) and a chelating agent
02/13/2007US7175836 Cosmetics can be formulated to manipulate light transmission; for enhancing facial radiance; water-in-oil emulsifying silicone surfactant; crosslinked silicone elastomer; and a conjugated linoleic acid
02/13/2007US7175835 stabilized against color and viscosity degradation; protect exposed skin against sunburn, cancer and even photoaging
02/13/2007US7175658 Coated with fibronectin on the interior surface, and having endothelial cells genetically altered to express a full-length human fibulin-5 polypeptide seeded and cultured on the interior surface of the tubular element; better adhesion of cells to the graft
02/13/2007CA2463976C N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
02/13/2007CA2387198C Method for treating hair loss using thyromimetic compounds
02/13/2007CA2361288C Mutual prodrug of amlodipine and atorvastatin
02/13/2007CA2359744C Cephalosporins and homologues preparations and pharmaceutical compositions
02/13/2007CA2359510C .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
02/13/2007CA2358840C Methods and kits comprising an estrogen agonist/antagonist for improving vascular health
02/13/2007CA2295119C Use of a specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
02/13/2007CA2285037C Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
02/13/2007CA2266378C Use of sibutramine analogues to lower lipid levels
02/13/2007CA2254759C Inhibitors of prenyl transferases
02/13/2007CA2233501C Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
02/13/2007CA2220649C 4-hydroxy-piperidine derivatives
02/13/2007CA2194399C Novel carbapenem derivative
02/13/2007CA2123241C Nucleosides and oligonucleotides having 2'ether groups
02/13/2007CA2122236C Quinolines and their analogs
02/13/2007CA2084987C Nucleic acid ligands
02/12/2007WO2008041966A2 Broad spectrum antibacterial compounds
02/12/2007CA2617123A1 Broad spectrum antibacterial compounds
02/12/2007CA2553115A1 Modulation of peroxisome proliferation-activated receptors
02/09/2007CA2618974A1 Nanoemulsion compositions having anti-inflammatory activity
02/08/2007WO2007016679A2 Combination immediate release controlled release levodopa and carbidopa dosage forms
02/08/2007WO2007016677A2 Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
02/08/2007WO2007016676A1 Tizanidine compositions and methods of treatment using the compositions
02/08/2007WO2007016674A2 2-aminoaryl pyridines as protein kinases inhibitors
02/08/2007WO2007016656A2 Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders
02/08/2007WO2007016650A2 M3 muscarinic acetylcholine receptor antagonists
02/08/2007WO2007016630A1 Sterol fortified beverages
02/08/2007WO2007016610A2 Antibacterial agents
02/08/2007WO2007016582A2 Amorphous aprepitant coprecipitates
02/08/2007WO2007016578A2 Prenylflavonoid formulations
02/08/2007WO2007016563A2 Alcohol resistant pharmaceutical formulations
02/08/2007WO2007016538A2 Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
02/08/2007WO2007016532A2 Mutations and polymorphisms of hdac4